Partnerships – I-Mab | Pioneering the Next Generation of Immuno-Oncology

Strategic Partnering Model

> 15 deals

~$1.5B total deal value

Innovation

Commercial
Partnerships

> 5 deals

~$345M total deal value

Global
Partnerships

Including the landmark deal with AbbVie

Note: Refers to the aggregate value for the relevant deals that the Company entered into on a cumulative basis. For details of each relevant deal, please refer to the disclosure filed or furnished by the Company with the SEC.

Landmark Deals

Global Strategic Partnership with AbbVie

Focusing on Certain New CD47 Antibodies in Development

Future milestone payments up to $1.295B + Royalties*

I-Mab will continue to prioritize lemzoparlimab in China with the potential to be first-to-market.

* I-Mab will be eligible to receive, and AbbVie will pay, up to US$1.295 billion in the development, regulatory and sales milestone payments, and the tiered royalties at rates from mid-to-high single digit percentages on global net sales outside of Greater China for certain new anti-CD47 antibodies currently in development, or the original milestone payments and tiered royalties previously disclosed in I-Mab’s Form 20-F for the fiscal year 2021 for other licensed products.

Commercial Partnership with Jumpcan

Focusing on Commercializing Eftansomatropin Alfa in China

Total aggregate value under the agreement $315M + Royalties / Shared Profits*

This deal brings together the strengths of I-Mab’s leadership in innovation and Jumpcan’s leadership in pediatric medicine in China to accelerate the commercialization of eftansomatropin alfa.

* Jumpcan pays US$35 million upfront and US$280 miilion upon development, registration, and sales milestone achievements. Sharing profits on a 50/50 basis, I-Mab is entitled to receive tiered low double-digit royalties on net sales of product.